Amgen: Lymphoma, Non-Hodgkin trials

The registry lists 16 Lymphoma, Non-Hodgkin studies with Amgen as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 1 5Phase 2 9Phase 3 2No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's LymphomaCompletedNCT02961881Phase 1Results posted
• Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHLCompletedNCT02910063Phase 2/3Results posted
• Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to RituximabCompletedNCT02747043Phase 3Results posted
• Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk ChemotherapyCompletedNCT02178475Results posted
• A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With LymphomaCompletedNCT00283439Phase 1/2Results posted
• Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHLCompletedNCT00274742Phase 1Results posted
• AMG 319 Lymphoid Malignancy FIHCompletedNCT01300026Phase 1
• IMPACT Non Hodgkins Lymphoma (NHL) StudyCompletedNCT00903812
• Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or VorinostatCompletedNCT00791011Phase 1
• Treatment for Subjects With Non-Hodgkin's LymphomaCompletedNCT00117897Phase 2
• A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's LymphomaCompletedNCT00117455Phase 2
• Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's LymphomaCompletedNCT00115193Phase 2
• Pegfilgrastim PBPC Mobilization StudyCompletedNCT00066092Phase 2
• Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)CompletedNCT00044902Phase 2
• Study of T900607-Sodium in Previously Treated Patients With Non-Hodgkin's Lymphoma.TerminatedNCT00043459Phase 2
• Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's LymphomaStatus unknownNCT00005959Phase 2